Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months by Purnomo, Andy et al.
 88
Hasford Scoring System and Hematologic Response with ImatinibPurnomo A, et al.
RESEARCH ARTICLE
Association between Hasford Scoring System and 
Hematologic Response in Chronic and Accelerated Phase of 
Chronic Myelocytic Leukemia Patient with Imatinib for 
Three Months 
Andy Purnomo, Ugroseno Yudho Bintoro, Made Putra Sedana, Ami Ashariati
Hematology Oncology Medic Sub-specialist Program, Department of Internal Medicine, Faculty of Medicine,
Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia
Background: Hasford score is a scoring system which was made in interferon treatment era to assess chronic myelocytic 
leukemia (CML) prognosis. Complete hematologic response (CHR) is the milestone of prognosis evaluation. CHR achievement 
will significantly increase survival. Imatinib is a revolutionized treatment that change the prognosis of CML. With the advent 
of  Imatinib, lessened the prognostic impact of the Hasford score to predict prognosis. 
Materials and Methods: An observational analytic with prospective cohort study conducted in oncology outward division 
Dr. Soetomo hospital Surabaya, from July until October 2018. Hasford score determined in 32 patients at the beginning of 
the study, given imatinib and followed up regularly for 3 months to know the hematologic response. Data were analyzed 
using Fisher exact test which was considered significant if p<0.05. 
Results: Median age was 39 years old, male 37.5% and female 62.5%, the median spleen was 18 cm, median hemoglobin 
was 9.1 g/dL, median leukocyte was 180x109/L, median thrombocyte  was 645x109/L, median eosinophil was 2.9%,  median 
basophil was 4.6%, median myeloblast was 6%. Hasford score showed 3.1% in low risk, 25% in intermediate risk and 71.9% 
in high risk. As much as 78.1% complete hematologic response was found in patient, and 21.9% was incomplete.
Conclusion: There was no association between Hasford scoring system and hematologic response in chronic and accelerated 
phase of chronic myelocytic leukemia patient with imatinib for three month. Hasford score had no impact in hematologic 
response with imatinib.
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Introduction
Chronic myelocytic leukemia (CML) is a myeloproliferative 
disease marked by leukocytosis, bone marrow hyperplasia 
and splenomegaly with the appearance of Philadelphia 
chromosome as its signature which inside there was a 
breakpoint cluster region protein (BCR)-Abelson murine 
leukemia viral oncogene homolog (ABL) gene fusion that 
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was form because of a reciprocal translocation between the 
long arm of ABL1 gene of the chromosome 9 with the short 
arm of BCR gene of the  chromosome 22 and written as 
t(9;22) (q34;q11). Philadelphia chromosome was proven 
to carry a unique fusion gene called BCR-ABL, which was 
believed to be the main cause of CML in chronic phase.1
 Around 15% of all leukemia around the world was 
CML. CML incidence in some countries varies even when 
there were not a lot of differentiations between them. Around 
4,000-5,000 new cases were diagnose in the USA annually. 
CML incidence is at 1.6-2.0 cases per 100,000 people each 
year. In China, it was estimated that 0.39-0.55 per 100,000 
population with the median age of 45-50 years and with 
the male to female ratio of 1.5:1. In Thailand it was around 
0.5 in every 100,000 population with the median age 36-38 
years old and with the male and female ratio of 1.7:1. In 
Indonesia, CML incidence was at 1.7 per 100,000 residents 
in the general hospital Dr. Soetomo of Surabaya. There 
was an increase in incidence where in 2006, there were 58 
patients mostly at the age of  30-40 years old, but in 2014 
there were 160 CML patients.2 Even if CML could occur 
at all age groups, its incidence increased at every decade 
of life, it makes the disease to become an adult disease. 
According to Surveillance, Epidemiology and End Result 
(SEER), the average age when the diagnosis of the disease 
was 66 years old, a much higher age than reported on a lot of 
clinical trial. This disease also appeared more often in male 
patients that female patients (2.2:1.3).3
 There were three known important risk factor scores in 
CML, which were Sokal, Hasford and European Treatment 
and Outcome Study (EUTOS) score, which was made in 
different time and use to grade the prognosis of CML.4 
Hasford score originated from a multivariate survival 
analysis in 981 chronic phase CML patients which were 
treated in 1983-1994. All of those patients were treated with 
only a single interferon alpha medicine or combine with 
other therapy. Where as in Hasford’s research low risks were 
discovered in 40.6% of the patients, intermediate risks in 
44.7% of patients and high risks in 14.6% of patients. This 
score was validated in a separate cohort research on 322 
CML patients.5 Several other researches about the prognosis 
score showed the following result. Sinha, stated that 
Hasford score was a better predictive prognosis indicator 
compared to Sokal, whereas Hasford score had two extra 
variables among them were the presentation of eosinophil 
and Basophil, this was not the case with the other score. 
The more eosinophil and basophil the worse the prognosis. 
Basophil was the source of angiogenesis inflammation 
process and also a source of fibrogenic molecules such as 
vascular endothelial growth factor or hepatocyte growth 
factor. Basophil also contain vasoactive substances such 
as histamine and cytokine dissolving enzyme, dipeptidyl-
peptidase IV that cause the mobilization of stem cell and the 
extra medullar spreading of stem cell and progenitor cell. 
Basophil also produced autocrine growth factor in CML.6 
Thomas also stated that Sokal score was no longer the best 
suited to predict CML patients survival.7 Dybko stated that 
Hasford score was still usefull as a tool to differentiate low 
and intermediate risks in achieving molecular response 
where  as  Sokal  and  EUTOS  did  not.8  To  this  day 
Sokal score was still the main score that was widely use, 
because of that researches in Hasford score was still need to 
be conducted.
 Hematologic response was an important point to asses 
a prognosis. This response was evaluated in the first three 
months. Failure to reach a complete hematologic response 
in three months is rare and usually signed a bad prognosis.9 
Complete hematologic response (CHR) was seen in 74% 
of patients that received Imatinib treatment.10 Bilen stated 
that CHR also occurred in 100% who received Imatinib. 
CHR was seen in 91% of patients with Imatinib.11 CHR was 
also seen in 90% of patients with Imatinib.12  Hematologic 
response also occurred in 52% of blastic crisis phase CML 
patients that received Imatinib.13 Studies on therapeutically 
hematologic response were very important regarding 
prognosis and  its simple and economical nature to be 
conducted. 
 Imatinib was a medicine use in several cancers with 
positive Philadelphia chromosome (Ph+) therapy like CML. 
The five years survival rate for CML patients increased twice 
from 31% (before imatinib) in 1993 to 59% for those who 
were diagnose on 2003-2009 with imatinib.  Annual mortality 
rate decreased from 10-20% to about 2%. With introduction 
of tyrosine kinase inhibitor (e.g., imatinib, nilotinib, 
dasatinib) into CML therapy lessened the prognostic impact 
of the prognostic factor. Pretreatment prognostic factor like 
Hasford lost much of clinical relevance regarding prognosis 
and to select therapies.14 These prognostic scales require 
revalidation given the dramatic impact of conversion to 
tyrosine kinase inhibitor treatment.15  Based on the reviews 
and considerations above, the researcher wants to know 
the association between Hasford score and hematological 
response in three months of Imatinib treatment. It was 
hoped that from this research, data can be provided to help 
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Table1. Characteristic of the CML patients.
determine the role of  Hasford score toward theurapeutical 
hematological response in this imatinib therapy era. 
Materials and methods
This research was an analytic, cohort prospective study using 
primary data conducted in the oncology outward division, 
Dr. Soetomo Hospital, Surabaya, from July-October 2018. 
The target populations of this research were CML BCR-
ABL positive patients which had not Imatinib treatment. 
The inclusion criteria was new male or female patients 
above the age of 18 years old and agreed to participate in 
this research which were proven in an informed consent. 
The exclusion criteria were patients who had liver cirrhosis, 
chronic hepatitis B or C and sepsis. Meanwhile the drop 
out citeria were pregnant (amenorrhea with pregnancy test 
positive), blastic crisis transformation (blast count >30%), 
patient could not take imatinib for less than 1 week, and loss 
of treatment monitoring.
 The starting dose for Imatinib was at 400 mg. If there 
was a drug side effect grade 3 or 4, the dose would be 
reduced to 300 mg.
  
Hasford Scoring System
The examination of BCR-ABL gene transcript of the 
CML patients in this research was conducted through 
real time PCR method using GeneXpert machine. If 
resulted  positive,  patient’s age, spleen size, and count of 
hemoglobin, leukocyte, thrombocyte, eosinophil, basophil 
were recorded. Examination of blood count using Sysmex 
XN-1000 machine. The examination of the myeloblast 
count was taken from the peripheral blood smear examined 
by two examiners, one examiner weas from clinical 
pathology division, while the other one was from internal 
medicine division. Researcher conducted an inter-rater 
agreement between the examiners. Chronic phase of  the 
CML if myeloblast count <15%  and accelerated phase if 
myeloblast count 15-30%. Hasford score was calculated 
using Hasford calculator online, then Hasford score was 
grouped into three categories, which were low (≤780), 
intermediate (780-1480) and high (≥1481). 
Hematologic Response
The researches subject was given with Imatinib therapy and 
then reexamined. The reexamination included symptoms, 
blood test, peripheral blood smear, and spleen size every 
months for three months to determine the hematologic 
response of the patients that was grouped to complete 
hematologic response define by no sign and symptoms 
of disease with disappearence of palpable splenomegaly, 
leukocytes ≤10x109/L, thrombocytes ≤450x109/L and no 
immature cells such as myelocytes, promyelocites, and 
blasts in peripheral blood smear, otherwise was incomplete 
hematologic response. 
Statistical Analysis
Hasford score were ordinal data. Hematologic response were 
nominal data. The data was non parametric and presented as 
a median. All of the data from the research was tabulated 
and analyze using the SPSS software version 18 to calculate 
the significance value statistically. Statistical analysis was 
performed using fisher exact test, with significance level 
was set at p<0.05.
Results
Characteristic of CML Patients 
At the end of the research there were 32 subjects. The 
researcher subject dominated by female, young age with 
massive splenomegaly, anemia, severe leukocytosis, 
thrombocytosis, and basophila. Myeloblast markly 
increased in blood smear examination. Detail characteristic 
of the CML patients was shown in Table 1.
Median (Range)
Male, n (%)                                     12 (37.5)
Female, n (%)                                     20 (62.5)
39 (18-63)
18 (0-30)
9.1 (5.0-12.3)
180 (1-678)
  645 (61-1355)
2.9 (0-11)
4.6 (0-25)
6 (0-17)
Characteristic (n=32)
Gender
Age (years old) 
Spleen (cm)                                  
Hb (g/dL)                                 
Leukocyte (109/L)                              
Thrombocyte (109/L)                              
Eosinophil (%)                                    
Basophil (%)                                     
Myeloblast (%)                                      
91
Print ISSN: 2527-4384, Online ISSN: 2527-3442DOI: 10.21705/mcbs.v3i2.56Molecular and Cellular Biomedical Sciences, Vol.3 No.2, September 2019, p.88-94
Table 2. The Hasford score distribution.
Distribution of Hasford Score in CML Patients 
The Hasford score were consisted of three groups which 
were low, intermediate and high. Most of the research 
subjects were classified in the high Hasford score. Hasford 
score distribution of this study was shown in Table 2.
Hasford n (%)
Low 1 (3.1)
Intermediate 8 (25)
High 23 (71.9)
Distribution of Hematologic Response in CML Patients 
with  Imatinib Treatment
Hematologic response distribution from the complete  and 
incomplete hematologic response was shown in Table 3. 
Complete hematologic response occurred in most of the 
patients.
Table 3. Hematologic response distribution.
Hematologic Response n (%)
Incomplete 7 (21.9)
Complete 25 (78.1)
Distribution of Hasford Score with Hematologic Response 
in CML Patients with Imatinib Treatment
Distribution of low, intermediate, high score and the 
complete and incomplete hematologic responses showed 
that all of the low and intermediate Hasford score displayed 
a complete hematologic response where as in the high 
Hasford score the majority of the patients also displayed 
complete hematologic response (Table 4).
Incomplete
n (%)
Complete
n (%) Total
Low 0 1 (100) 1
Intermediate 0 8 (100) 8
High 7  (30.4 ) 16 (69.6) 23
Hematologic Response
Hasford
Table 4. Distribution of Hasford score with hematologic 
response.            
The Statistical Association Test between Hasford Score 
and Hematologic Response in Chronic and Accelerated 
Phase CML Patient with  Imatinib Treatment
To determine the association test, expectation value was 
conducted in advance. Since an expectation value of  <5 
reach 50% of the total cell (3/6) then Chi Square test were 
not up to the conditions, so the Fisher exact test was used. 
The Fisher exact test results showed p=0.179 (statistically 
significance is p<0.05), then it can be concluded that 
there were no association between Hasford score with 
hematologic response in chronic myelocytic leukemia 
chronic and accelerated phase patients that acquired three 
months Imatinib therapy. The expectation value of  Hasford 
score with Hematologic Response was shown in Table 5.
Table 5. The expectation value of  Hasford score with 
hematologic response.
Incomplete Complete
Low 0.2 0.8
Intermediate 1.8 6.3
High 5 18
Hasford
Hematologic Response
Discussion
Characteristic of CML Patient 
At the end of this research, it was discovered that the 32 
subjects dominated by female (62.5%) with the median 
age of 39 (18-63) years old. Result from this research 
was similar with a cohort research conducted in Turkey 
during 2006-2009, that in 31 research samples were also 
dominated by female (61.9%) with the median age of 48.9 
(18-75) years old.16 This research was a little bit different 
with a prospective research in Pakistan that was conducted 
in 2001-2006 where there were 136 patients dominated by 
male (63%) with the median age 33 (12-65) years old.17 
Another retrospective study in Egypt from 2008-2013 that 
had a much bigger sample which was at 167 patients, was 
dominated by male (64.7%) with the median age of 49 
(23-74) years old.18 In China, a retrospective study done 
in 2006-2013, acquired 210 patients dominated by male 
(60%) with the median age of 42.22 (6-84) years old.19 A 
multicenter retrospective study by Hasford in 1983-1994 in 
1303 samples discovered a result dominated by male with 
the median age  of 49 years old.5 The small sample amount 
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in this research was caused by the use of primary data (new 
patients) with the short research time of four months and 
two drop outs, where in the other hand, other researches 
required a minimal time of three years and uses secondary 
data (medical record). This research acquired a majority of 
female in the result and this was caused by the demographic 
factor, hence the amounts of female respondence was 
more than male. This research had the young age median, 
similar with the research that was conducted by Usman17 
which caused CML to become a disease that was not only 
experience by elderly people (in western country, CML 
was averagely diagnoses in 66 years old) but people with 
younger ages could also experience this disease.
 In this research, from physical examination, the 
biggest spleen size with the median of 18 (0-30) cm was 
discovered which reached three times size from the result 
of Bilen’s research with the median of 5.87 (0-20) cm, Xia’s 
research with the median of 6.73 (0-21) cm, and Tamer’s 
research with the median of 5 (2-14,5) cm also Hasford’s 
research with the median of 3.4 (0-30) cm.16,18,19 This was 
caused by the subjects who visited the hospital with severe 
condition and large tumor burden.
 In this research the subjects came to the hospital 
with anemia, severe leukocytosis and thrombocytosis. 
From the examination of the marginal blood smear, the 
median hemoglobin of 9.1 g/dL, leukocytes of 180x109/L, 
thrombocytes of 645x109/L, was found that was similar 
with Xia’s research where median hemoglobin of 9.6 g/
dL, leukocytes of 188x109/L, thrombocytes of 363x109/L 
was found and in Bilen’s research where the percentage 
of haematocrit at 34.32 (23-49)%,  leukocytes of 141.23 
(13-437)x109/L, thrombocytes at 513 (134-1571)x109/L 
was found. It was different with the Hasford’s own 
research where a result of hemoglobin at 12 (2-18.2)  g/
dL,  leukocytes at 68 (1-571)x109/L, thrombocytes at 360 
(34-3050)x109/L was found.16,19 This difference happened 
because in the western country, most of the patients visited 
the hospital without symptoms and the disease was found 
by health care screening test, where in the other hand, in 
the developing countries including in Indonesia, the patient 
came to the hospital caused by symptoms.
 From the differential count in this research, it was found 
that the median of eosinophil was 2.9 (0-11)%, basophil was 
4.6 (0-25)%, this was similar with Yamamoto’s research 
with eosinophil at 2.5 (0-13)%, basophil at 5 (0-25.5)%, and 
Xia’s research with eosinophil at 3.5%,  basophil at 4.6%, 
Bilen’s research with eosinophil  at 3 (1-8)%, basophil 2.8 
(0-9)%, Hasford’s research with eosinophil 2 (0-20)%, 
basophil 3 (0-21)%, Tamer’s research with eosinophil 2 
(0-15)%, basophil 4 (1-15)%.16,18-20 Excess basophil was 
a sign  of CML, and this variable was the superiority that 
Hasford score had compared to Sokal’s score in evaluating 
prognosis. 
 From the peripheral blood smear examination it was 
discovered the median of myeloblast at 6 (0-17)% which 
was highest when compare to other researches such as Xia 
with myeloblast of 1.46%, Hasford with myeloblast at 1 (0-
15)%, Yamamoto with myeloblast at 0 (0–14)%, and Tamer 
with myeloblast at 2 (0-7)%.16,18-20 The high myeloblasts 
showed a bad prognosis which was caused by the subject of 
this research being in a chronic and accelerated phase where 
in the other hand in other researches it was only chronic 
phase.  
Distribution of Hasford Score in CML Patient 
In this research it was discovered that the majority of the 
subjects was classified in high score with the sequence of 
the low, intermediate and high Hasford score each at 3.1%, 
25% and 71.9%. It was difference with Kuntegowdanahalli’s 
research which was dominated by the intermediate score 
with the sequence of 20.2%, 62.1%, 17.5%.21 Yamamoto 
with the sequence of 41.4%, 49.6%, 9.0%, Castagnetti  with 
the 38%, 62%, 0. Tamer with 38.9%, 49.1%, 12%., Hasford 
with 38%, 51%, 11 %.18,20,22 Even in other researches it was 
dominate by low score such as Xia with 48.1%, 43.8%, 
8.1%.19 In the western countries the highest score was only 
at 10-20%. The abundant high scores in this research was 
caused by the acceleration phase which was also being 
researches, where as in other researches it was only chronic 
phase that was being researched. 
Hematologic Response Distribution in CML Patients Who 
Still Acquiring Imatinib Treatment
In this research the Complete Hematologic Response (CHR) 
occurred in 78.1 % of the patients. Bilen’s research stated 
that 100% of the patients achieved CHR in three months, 
where 80.6% of patients achieved CHR in one month and 
19.4% achieved  CHR within 2 months.16 Usman stated that 
117 (86%) CHR patients with 79 patients in between them 
having low score.17 Reksodiputro stated that CHR occurred 
at 74% of the patients that received Imatinib treatment.10 
Roko stated that CHR occurred in 91% CML patients with 
Imatinib.11 Even hematologic response could also happen in 
52% of CML blastic crisis phase that received Imatinib.13 
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This research was similar with other researches where the 
CHR value was high enough even when the acceleration 
phase was included in this research. In this research 7 
(21.9%) patients did not achieve CHR because of leukocytes 
above 10 x 109/L (6 patients) and splenomegaly (1 patient). 
Distribution of Hasford Score Toward Hematologic 
Response in CML Who Still Acquiring Imatinib Treatment
In this research all of the intermediate and low score 
(100%) reached complete hematologic response where in 
the other hand 69.6% of the high score patients also reached 
complete hematologic response. This showed that complete 
hematologic response occured in the majority of this score 
with imatinib treatment. Even in the high score Imatinib 
also give a good therapy response.
 Association between Hasford score with Hematologic 
response in accelerated and chronic phase of CML who still 
acquiring Imatinib treatment for three months.
 In this research this statistical test result showed 
p=0.179, so it can be concluded that there was no 
association between Hasford score with Hematologic 
response. Research by Tamer stated that there was a 
substantial difference between Hasford scores (p<0.0001) 
at the therapy failure value whereas the high score value of 
therapy failure was higher compare to the low score. A lot of 
researches discussed about the correlation between Hasford 
score with the survival, cytogenetic and molecular therapy 
response, but there were very rare for a research to connect 
between Hasford score and hematologic response. It was 
difficult to compare the result of this research with other 
researches because of the rarity of a similar research that has 
been conducted. 
 This research was affected by some limitations, one of 
them is the existence of a disturbing variable of hydroxyurea 
medicine usage, before the research was conducted, this 
could affect the Hasford score, also the small amount of 
sample in this research caused by the lack of new CML 
patient that fulfilled the conditions of the research and the 
research’s short time. 
Conclusion
There was no association between Hasford score and 
hematologic response in chronic and accelerated phase of 
CML patients that received Imatinib treatment for three 
months. Hasford score had no impact in hematologic 
reponse with imatinib. 
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